Masterflex SE has reported preliminary figures for the 2025 financial year that align with its forecasts, achieving new record earnings and strengthening its financial position. The company's consolidated revenue rose to EUR 102.6 million, a 4.6% increase from the previous year's EUR 98.1 million, meeting its projected range of EUR 100 million to EUR 105 million. This performance occurred despite what the company describes as a continuing challenging economic environment.
The significance of these results lies in Masterflex's demonstrated operational resilience and strategic positioning. The company achieved a 7.4% increase in operating EBITDA to EUR 19.5 million and a 9.8% rise in operating EBIT to EUR 14.0 million, both representing new records. Even with currency losses and start-up costs for a new site in Morocco, the operating EBIT margin improved to 13.6% from 13.0% in the previous year. EBIT reached EUR 13.7 million, within the forecasted range of EUR 12 million to EUR 15 million.
Particularly noteworthy was the performance of the medical technology segment, which experienced dynamic demand growth. The share of high-margin medical technology in consolidated revenue increased from 18% in 2024 to 21% in 2025, indicating successful strategic focus on this profitable area. The US subgroup performed especially well during the year. While demand in industrial customer sectors grouped under "Tech" and in the trading business declined moderately, the order backlog remained stable at EUR 19.8 million at year-end.
Masterflex significantly strengthened its financial foundation, with the equity ratio improving to 73.3% from 67.7% in the previous year. Financial liabilities were substantially reduced, with net debt falling to EUR 2.7 million from EUR 9.0 million. The debt ratio, measured as net debt to EBITDA, improved to 0.1 from 0.5. This enhanced financial stability provides the company with greater flexibility for future investments and growth initiatives.
Dr. Andreas Bastin, CEO of Masterflex SE, commented on the results, stating that the company met its forecasts, achieved solid revenue growth, and slightly increased profitability through continuous efficiency improvements. He noted particular satisfaction with the development of the medical technology business and the further strengthening of the balance sheet. The company's financial reports and additional information are available through its investor relations contact at www.crossalliance.de.
These preliminary figures remain subject to confirmation by auditors and approval by the Supervisory Board. The complete 2025 consolidated financial statements and the 2026 forecast will be published on March 31, 2026. The original release containing this information can be viewed on www.newmediawire.com.
